BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  Cutera Announces First Quarter 2024 Financial Results

  Cutera, Inc., a leading provider of aesthetic and dermatology solutions, reported financial results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  17 min read
• Business

  Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

  Kezar Life Sciences, Inc., a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, reported financial results for the first quarter ended March 31, 2024 and provided a business update.

  May 9, 2024

   · 

  8 min read
• Business

  Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

  Arrowhead Pharmaceuticals, Inc. announced financial results for its fiscal 2024 second quarter ended March 31, 2024.

  May 9, 2024

   · 

  10 min read
• Business

  Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

  Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS) announces first quarter 2024 financial results and provides a corporate update.

  May 9, 2024

   · 

  9 min read
• Drug Development

  Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC).

  May 9, 2024

   · 

  6 min read
• Business

  Nektar Therapeutics Reports First Quarter 2024 Financial Results

  Nektar Therapeutics reported financial results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  9 min read
• Business

  Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

  Guardant Health, Inc., a leading precision oncology company, reported financial results for the quarter ended March 31, 2024.

  May 9, 2024

   · 

  16 min read
• Business

  Natera Reports First Quarter 2024 Financial Results

  Natera, Inc., a global leader in cell-free DNA and genetic testing, reported its financial results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  13 min read
• Business

  NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

  NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update.

  May 9, 2024

   · 

  10 min read
• Business

  CytoSorbents Reports First Quarter 2024 Results

  CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024.

  May 9, 2024

   · 

  16 min read